# A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)

> **NCT07648914** · PHASE3 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 446 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07648914
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648914, "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07648914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*